ACADIA Pharmaceuticals Inc. (ACAD)

46.33
1.09 2.41
NASDAQ : Health Technology
Prev Close 45.24
Open 45.53
Day Low/High 45.50 / 47.79
52 Wk Low/High 14.01 / 45.87
Volume 2.05M
Avg Volume 2.05M
Exchange NASDAQ
Shares Outstanding 154.03M
Market Cap 6.56B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., To Board Of Directors

ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., To Board Of Directors

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Unilever, Visa and NXP Semiconductors Are Superior Stocks, Says Mott Capital Manager

Unilever, Visa and NXP Semiconductors Are Superior Stocks, Says Mott Capital Manager

Unilever shares are up over 7% this year and the company should continue to perform well.

Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager

Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager

Unilever (UL) shares are up over 7% so far this year and the consumer staples giant will continue to perform well as it expands its reach in the emerging markets.

Weak On High Volume: ACADIA Pharmaceuticals (ACAD)

Weak On High Volume: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a weak on high relative volume candidate

Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)

Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Present At The 24th Annual Credit Suisse Healthcare Conference On November 10, 2015

ACADIA Pharmaceuticals To Present At The 24th Annual Credit Suisse Healthcare Conference On November 10, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

3 Stocks Spiking on Big Volume

3 Stocks Spiking on Big Volume

Here's a technical look at how to trade three stocks rising on unusual volume today.

ACADIA Pharmaceuticals Announces FDA Priority Review Of NUPLAZID™ (Pimavanserin) New Drug Application For Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Announces FDA Priority Review Of NUPLAZID™ (Pimavanserin) New Drug Application For Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce Third Quarter Financial Results On November 5, 2015

ACADIA Pharmaceuticals To Announce Third Quarter Financial Results On November 5, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Acadia's New Drug Could Have Potential for Investors

Acadia's New Drug Could Have Potential for Investors

Acadia Pharmaceuticals has been buffeted in recent months but its treatment for psyhosis related to Parkinson's disease has great potential.

Interesting ACAD Put And Call Options For November 20th

Interesting ACAD Put And Call Options For November 20th

Investors in Acadia Pharmaceuticals Inc saw new options become available this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new November 20th contracts and identified one put and one call contract of particular interest.

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2015 Healthcare Conference On September 29, 2015

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2015 Healthcare Conference On September 29, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)

Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Perilous Reversal Watch: ACADIA Pharmaceuticals (ACAD)

Perilous Reversal Watch: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "perilous reversal" (up big yesterday but down big today) candidate

Acadia Pharmaceuticals (ACAD) Stock Climbs on Drug Application for Parkinson's Treatment

Acadia Pharmaceuticals (ACAD) Stock Climbs on Drug Application for Parkinson's Treatment

Acadia Pharmaceuticals (ACAD) shares are rising after the company submitted a new drug application for its Parkinson's related psychosis treatment.

Steve Davis, Chief Executive Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)

Steve Davis, Chief Executive Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Submits New Drug Application For NUPLAZID™ For The Treatment Of Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Submits New Drug Application For NUPLAZID™ For The Treatment Of Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market leader candidate

The Trader Daily: Let's Welcome Biotechs to the House of Pain

The Trader Daily: Let's Welcome Biotechs to the House of Pain

The bulls can show them around the place.

Today's Water-Logged And Getting Wetter Stock: ACADIA Pharmaceuticals (ACAD)

Today's Water-Logged And Getting Wetter Stock: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Analysts' Actions -- Intel, Texas Instruments and Viacom

Analysts' Actions -- Intel, Texas Instruments and Viacom

Here are Friday's top research calls, including downgrades of Intel and Texas Insturments

ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals Announces Publication Of Data From Its -015 Open Label Safety Study In Parkinson's Disease Psychosis In The Journal Of The American Medical Directors Association

ACADIA Pharmaceuticals Announces Publication Of Data From Its -015 Open Label Safety Study In Parkinson's Disease Psychosis In The Journal Of The American Medical Directors Association

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals Announces Senior Management Appointments In Manufacturing, Quality, Compliance, Access And Reimbursement And Business Development

ACADIA Pharmaceuticals Announces Senior Management Appointments In Manufacturing, Quality, Compliance, Access And Reimbursement And Business Development

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals To Announce Second Quarter Financial Results On August 6, 2015

ACADIA Pharmaceuticals To Announce Second Quarter Financial Results On August 6, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals (ACAD) Strong On High Relative Volume Today

ACADIA Pharmaceuticals (ACAD) Strong On High Relative Volume Today

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 24, 2015

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 24, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

ACADIA Pharmaceuticals Presents Integrated Data From Its Phase III Program With NUPLAZID™ (Pimavanserin) For Parkinson's Disease Psychosis At The 19th International Congress Of Parkinson's Disease And Movement Disorders

ACADIA Pharmaceuticals Presents Integrated Data From Its Phase III Program With NUPLAZID™ (Pimavanserin) For Parkinson's Disease Psychosis At The 19th International Congress Of Parkinson's Disease And Movement Disorders

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the...

ACADIA Pharmaceuticals To Present At The Jefferies 2015 Healthcare Conference On June 2, 2015

ACADIA Pharmaceuticals To Present At The Jefferies 2015 Healthcare Conference On June 2, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

TheStreet Quant Rating: D (Sell)